CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Soft Tissue Sarcomas
Medical News Today
Article Date: 25 Nov 2009 - 15:00 PST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced soft tissue sarcomas who have failed surgery and radiation. Soft tissue sarcomas...
Medical News Today
Article Date: 23 Oct 2009 - 3:00 PDT
Cancer patients don't have time to waste, yet many must endure a tedious process of elimination as physicians try several different treatments until identifying the one that is most effective against their particular type of tumor. Now researchers at the University of Virginia Health System have developed a breakthrough method that could one day eliminate this trial and error approach to treating many cancers.
* Positive top-line results from cancer drug phase II study
* Says it shows potential for treatment of front line NHL
* Positive results just nine days after drug disappointed
By Teis Jensen
COPENHAGEN, Aug 26 (Reuters) - The Danish biotech company Genmab said on Wednesday that it got positive top-line results from a phase II study of its Arzerra cancer drug, which is being co-developed with GlaxoSmithKline....
AJHO: The American Journal of Hematology/Oncology
August 18, 2009
● RESEARCHERS OF THE CHILDREN'S ONCOLOGY GROUP HAVE DEVELOPED a new chemotherapy regimen known as ABVE-PC to treat patients with pediatric Hodgkin lymphoma (HL). Led by Cindy Schwartz, MD, director of pediatric hematology/ oncology at Hasbro Children's Hospital in Providence, Rhode Island, the group combined six different drugs into a dose-dense regimen that achieves rapid early response and limits...
Liposomal Doxorubicin Offers Better Tolerability, but No Improvement in Efficacy, Over Conventional Doxorubicin: Presented at WCTC
By Cameron Johnston
TORONTO -- August 13, 2009 -- Liposomal doxorubicin appears to have a slightly better side-effect profile than standard chemotherapy with conventional doxorubicin. But in a small trial of patients with advanced recurrent, medullary, and anaplastic thyroid cancers, there was little or no difference in efficacy between the...
